Shire’s Veyvondi approved in Europe for bleeding disorder
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
Read More
Tag: VWD
US expands use of Shire’s Vonvendi
US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
